Blueprint Medicines Dividend
Dividend criteria checks 0/6
Blueprint Medicines does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$8.28 |
| Dividend yield forecast in 3Y | 1.1% |
Recent dividend updates
No updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Apr 05
Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%
Dec 18Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance
Aug 02Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront
Jun 30Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook
Feb 17Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation
Nov 10Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)
Oct 15Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if BPMC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BPMC's dividend payments have been increasing.
Dividend Yield vs Market
| Blueprint Medicines Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (BPMC) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.9% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (BPMC) | 1.1% |
Notable Dividend: Unable to evaluate BPMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BPMC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate BPMC's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BPMC has not reported any payouts.